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Glaucoma is the most common optic neuropathy characterized by normal to raised intraocular pressure
(IOP), visual ﬁeld defects, loss of retinal nerve ﬁber layer, thinning of the neuroretinal rim, and cupping of
the optic disc. IOP reduction by medical, laser, or surgical therapies remains the only clinically proven
treatment of glaucoma. The challenges in glaucoma management are diverse. They include early
detection and diagnosis, setting of appropriate target IOP, choice of treatment, monitoring of quality of
life and sight, and compliance with the treatment. Early diagnosis can be made by assessing optic nerve
structure using imaging devices and optic nerve function through perimetry. Reducing IOP and con-
trolling its ﬂuctuations are considered to be the most important factors in limiting progression of
glaucoma. Selection of the best suitable therapy out of medical, surgical, or laser treatment options is yet
another management challenge. Patients suffering from glaucoma experience poor quality of life owing
to the diagnosis itself, functional visual loss, inconvenience and cost of treatment, and side effects of
treatment. All these factors lead to poor compliance, adherence, and persistence to treatment, and
further progression of the disease. It is, therefore, important that ophthalmologists keep all the afore-
mentioned factors in mind when managing patients with glaucoma.
Copyright © 2016, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Globally, glaucoma is the most common optic neuropathy, the
second common cause of blindness, and themost common cause of
preventable visual disability.1 Glaucoma includes a spectrum of
progressive optic neuropathies characterized by pathological
degeneration of nonmyelinated retinal ganglion cells, with struc-
tural damage at the level of optic nerve head. The commonpathway
in the pathogenesis of glaucoma is triggering of accelerated
apoptosis of the retinal ganglion cells.2 As a consequence of
neuronal death within the central visual pathway, clinical signs of
glaucoma start appearing. These signs include retinal nerve ﬁber
layer defects, thinning of the neuroretinal rim, and excavation of
the optic nerve head, commonly called cupping of the optic disc.
These structural changes lead to functional defects in the form of
irreversible visual ﬁeld loss.3
In the currently published literature on glaucoma, intraocular
pressure (IOP) is not considered to be a part of the deﬁnition of
glaucoma; however, it is the most easily modiﬁable risk factor tot and no ﬁnancial disclosures
Block, Johar Town, Lahore,
iety of Taiwan. Published by Elsevidecrease the risk of disease onset and progression.4 IOP reduction
by medical, laser, and surgical treatments remain the only clinically
proven treatment of glaucoma.5 However, Collaborative Normal
Tension Glaucoma study has exempliﬁed that lowering of IOP alone
is not entirely effective for all patients of glaucoma.6 In some pa-
tients, sufﬁcient IOP reduction to slow down or arrest the disease
process may be either difﬁcult or full of adverse effects of
treatment.
2. Magnitude and burden of the disease
According to the World Health Organization estimates of 2002,
the number of people blinded by glaucoma was 4.4 million (12.3%
of the blind people worldwide). The majority of those with glau-
coma remain undetected, and estimates of people afﬂicted by
glaucoma and related blindness are made on the basis of data from
epidemiological studies. From these studies, it has been understood
that glaucoma affects all populations, but there is a disparity in
distribution. This disparity is either because of a higher prevalence
and racial predilection or because of a large population in these
regions resulting in a larger absolute number of persons with
glaucoma.7
The type of glaucoma also varies from region to region. Primary
open-angle glaucoma (POAG) is the predominant glaucoma iner Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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Australia. The highest prevalence of glaucoma in these regions is
observed in the African and Caribbean origin population in the USA
and the Caribbean. A study by Quigley8 among Latin Americans
revealed the prevalence of glaucoma to be intermediate between
those of Caucasians and black people.
Nearly half of the population with glaucoma resides in Asia,
which includes the three most populous countriesdChina, India,
and Pakistan. Prevalence surveys in Mongolia, Singapore, China,
and India have observed the prevalence of primary angle closure
glaucoma to be equal to that of POAG, and is similar to that of
Caucasians.9
The prevalence of combined glaucoma (primary and secondary)
in Tanzanian and South African studies was reported to be 5%. The
predominant type of glaucoma is POAG.
The total global estimate of POAG and PACG for the year 2020
was considered to be 60.5 million and 79.6 million respectively in
year 2010.
3. Challenges
3.1. Early detection and diagnosis
The anatomical and functional changes from glaucoma are
largely irreversible; therefore, early disease detection remains an
important strategy to prevent visual impairment. This has been
achieved by assessing optic nerve structure using imaging devices
and optic nerve function through perimetry. Imaging and peri-
metry techniques have improved considerably, and new strategies
are emerging to complement these established techniques.10 These
include retinal nerve ﬁber layer analysis and detection of retinal
ganglion cells apoptosis in vivo. Spectral-domain optical coherence
tomography in glaucoma offers the opportunity of objectively
measuring the retinal nerve ﬁber layer and its associated changes
with time. Although it can achieve a resolution of 3e6 mm, it is
dependent on establishing structural and functional relationships.
The ability to detect pre-perimetry glaucoma has been a goal in
clinical management of glaucoma for several decades.11 A tech-
nique termed as “detection of apoptotic retinal cells” has been
developed, which utilizes nonradioactive ﬂuorescent-labeled
annexin V and high-resolution imaging to enable real-time detec-
tion of apoptosis in retinal ganglion cells. The technology has been
demonstrated well in animal models but has to undergo Phase I
clinical trials for its safety assessment.12
3.2. Setting of IOP targets
IOP has been identiﬁed as the only modiﬁable risk factor, and
lowering of IOP to prevent progression of glaucoma is now the
backbone of glaucoma management. A growing body of evidence
shows that not only the mean IOP reduction is important, but also
control of ﬂuctuation of IOP plays amajor role in the preservation of
vision and visual ﬁelds.13
European Glaucoma Society has deﬁned the target IOP as
the mean IOP obtained with treatment that prevents furtherTable 1
Classiﬁcation of eyes based on severity of glaucoma.
Severity group Characteristics
Suspect 1 or 2 of the following: IOP >21 mmHg; suspicious disc or
Early Early glaucomatous disc features (e.g., C/D* <0.65) & (or) m
Moderate Moderate glaucomatous disc features (e.g., vertical C/D 0.7e
to 12 dB on HVF 24-2)
Advanced Advanced glaucomatous disc features (e.g., C/D* >0.9) & (or
C/D ¼ cup-to-disk ratio; HVF ¼ humphrey visual ﬁelds; MD ¼ mean deviation; VF ¼ visglaucomatous damage. Formulation of the target IOP is one of the
most important steps in treatment. It is generally assumed that
aiming to achieve at least a 30% reduction from the initial pressure
at which damage occurred is a useful arbitrary way to achieve the
initial target IOP. The target IOP is the IOP range at which the
clinician decides that progressive disease is unlikely to affect the
patient's quality of life (QOL). Besides, the target IOP can be
explained as the upper limit of a stable range of measured IOPs
deemed likely to retard further optic nerve damage.14
The target IOP is determined on the basis of the following fac-
tors: amount of glaucoma damage; the IOP at which the damage
has occurred; life expectancy of the patient; status of the fellow
eye; and family history of glaucoma.
It is recommended that the target IOP be recorded so that it is
accessible on subsequent patient visits. The target IOP is not a static
value; rather, it requires periodic re-evaluations. When setting the
target IOP, each eye is staged into one of four severity groups:
suspect, early, moderate, or advanced glaucoma based on the
following factors: assessment of the optic nerve and visual ﬁelds;
patient factors especially IOP; age; life expectancy; quality of life;
risk factors for progression; and patient's own input (Table 1)15.
However, it should be remembered that there is a ﬁne line be-
tween setting an appropriate goal to prevent optic nerve damage
and being overly aggressive in IOP lowering.
3.3. More target IOP recommendations
Stage each eye of the patient as normal, suspect, early, moderate,
or advanced glaucoma based on optic nerve and (or) visual ﬁeld
examination.
Set the upper limit of the initial target IOP range for each eye at
the ﬁrst visit and then re-evaluate at each visit based on stability/
change in structure and function of the optic nerve (i.e., Optic nerve
head (ONH) examination with or without additional imaging in-
formation as well as visual ﬁeld data). The suggested upper limit of
the target IOP as described by various studies is given in Table 2.15
IOP telemetry is done through a device called telemetric strain
gauge contact lens (Sensimed Triggerﬁsh).16 The device measures
the changes in corneal curvature with ﬂuctuation in IOP. Variation
of 1 mmHg produces a change of central corneal curvature radius of
~3 mm. A reading of 30-second duration is taken every 5 minutes
over a 24-hour period.17
4. Choice of treatment
The choice of treatment is multifactorial and depends on the
level of IOP, ﬂuctuation of IOP, stage of disease, pace of progression,
current treatment, and past treatments. Medical, laser, and surgical
treatments are available in almost all parts of the world, with var-
iations and preferences according to local populations. All the
currently available treatments are targeted toward IOP control,
which is a risk factor for glaucoma but not necessarily the sole
cause of disease progression. Recent exciting developments in
glaucoma management address these concerns. These include the
development of a new class of IOP-lowering medications known asC/D asymmetry of >0.2; suspicious 24-2 (or similar) VF defect
ild VF defect not within 10 of ﬁxation (e.g., MD better than 6 dB on HVF 24-2)
0.85) & (or) moderate VF defect not within 10 of ﬁxation (e.g., MD from 6 dB
) VF defect within 10 of ﬁxation (e.g., MD worse than 12 dB on HVF 24-2)
ual ﬁeld.
Table 2
Target intraocular pressures based on stage of glaucoma.
Stage Suggested upper limit of
target IOP
(Modiﬁed based on
longevity, QOL, & risk
factors for progression)
Evidence
Suspect in whom a clinical
decision is made regarding
treatment
24 mmHg with at least
20% reduction from baseline
OHTS
EGPS
Early 20 mmHg with at least
25% reduction from baseline
EMGTS
CIGTS
Moderate 17 mmHg with at least
30% reduction from baseline
CNTGS
AGIS
Advanced 14 mmHg with at least
30% reduction from baseline
AGIS
Odberg
AGIS ¼ Advanced Glaucoma Intervention Study; CIGTS ¼ Collaborative Initial
Glaucoma Treatment Study; CNTGS ¼ Collaborative Normal Tension Glaucoma
Study; EGPS ¼ European Glaucoma Prevention Study; EMGTS ¼ Early Manifest
Glaucoma Treatment Study; OHTS ¼ Ocular Hypertension Treatment Study.
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reducing IOP, and the development of non-IOP-dependent thera-
pies such as neuroprotection.18 Brimonidine and memantine are
the prototypemedicines that are in clinical use for neuroprotection.
The conventional treatment includes groups of drugs such as beta-
blockers, prostaglandin analogues, carbonic anhydrase inhibitors,
alpha agonists, and parasympathomimetics.
For longer than the past two decades, the paradigm of the drug
of ﬁrst choice has shifted from beta-blockers to prostaglandin an-
alogues. In case of poor IOP control, the add-on therapy is in the
form of ﬁxed combinations of two drugs available in almost all
parts of the world.
For patients who cannot tolerate medications or are inade-
quately controlled with medications, laser treatment continues to
be an excellent alternative in the developed parts of the world. The
laser may also be used as a primary treatment option in case of pre-
existing ocular surface disorder. The most common laser treatment
for glaucoma is argon laser trabeculoplasty. A new type of laser,
called micropulse laser trabeculoplasty, is currently being studied
as yet another option for effectively increasing drainage of eye ﬂuid
to lower IOP.
Trabeculectomywith or without adjuvants is still considered the
procedure of ﬁrst choice, especially in the developing world.
Modiﬁed procedures with variable outcomes include viscocana-
lostomy, nonpenetrating glaucoma surgery, shunts or tube im-
plants, collagen matrix implants, and high-frequency deep
sclerectomy.
All these procedures demand specialized training, expertise, and
equipment, which vary from region to region.
5. Quality of life and quality of sight
Patients suffering from glaucoma can lose QOL for several rea-
sons: thediagnosis itself, functional loss, inconvenienceof treatment,
side effects of treatment, and cost of treatment.19 Glaucoma therapy,
whether medical or surgical, can directly inﬂuence a patient's QOL.
Health-related QOL is an important outcome in glaucoma, and it can
be measured using either generic or vision-speciﬁc instruments.
Generic instruments include the Medical Outcomes Study Short
Form36, sickness impactproﬁle, EuroQOLHealthQuestionnaire, and
utility values among others.20 The most commonly used vision-
speciﬁc instrument is the 25-question version of the National Eye
Institute Visual Functioning Questionnaire.
Ocular surface disease is a group of disorders that affect various
components of the ocular surface tissues. It has become increas-
ingly common with growing age.21Glaucoma primarily affects patients in the 5the7th decades of
their lives; therefore, ocular surface disease poses an increased risk
to them, and more than 50% of patients with glaucoma and
receiving antiglaucoma medications have ocular surface disease in
at least one eye.22 This is of serious concern because ocular surface
disease results in dysfunction of the ocular tear ﬁlm with wide-
ranging symptoms and signs, including discomfort, grittiness,
burning, foreign body sensation, dryness, ulceration, and even
scarring. All these symptoms and signs negatively affect the QOL of
these patients.
Topical antiglaucoma medications have been associated with
ocular surface disease because they are instilled as drops into the
tear ﬁlm, where they interact with ocular surface tissues.
This interaction can involve the active agents themselves or
preservatives used to keep the bottles sterile and to stabilize the
active agents in solutions. Benzalkonium chloride is a detergent-
like preservative common to most antiglaucoma medications.
Studies23,24 have shown that benzalkonium chloride can damage
corneal and conjunctival epithelial cells and decrease conjunctival
goblet cell density, thereby reducing tear ﬁlm stability and pro-
moting dry eye.
Since antiglaucoma treatment is long term and often involves
multiple medical therapies, the potential for adverse interactions
increaseswith time. The negative effect of dry eye on QOL cannot be
overestimated. The reasons for nonadherence to treatment regi-
mens are multifactorial, but they at least partly depend on
discomfort of the eyes.25
6. Compliance, adherence, and persistence
Traditionally, compliance has been deﬁned as the extent to
which patients' behavior corresponds to physician's recommen-
dations.26 However, in recent literature, the term compliance has
been replaced by adherence and persistence. Adherence is the
measure of the degree to which a patient follows prescribed in-
structions during a deﬁned time period, and persistence, by
contrast, is a criterion that evaluates the time until the patient ﬁrst
discontinues the use of medications.
Patients routinely overestimate their adherence to eye drops. In
fact, 95% of patients claimed in one study (Glaucoma Adherence
and Persistency Study)27e30 that they never missed taking drops,
despite clear evidence that adherence of these patients was
dramatically lower.
Persistence with glaucoma medications has been found to be
low in several studies, varying from 20% to 64%.31 Glaucoma sus-
pects beginning latanoprost or a beta-blocker drop had persistency
rates of 39% and 25%, respectively, at 1 year.32
Clinical implications of nonadherence and nonpersistence are
serious. Determining, maintaining, and adjusting a target pressure
range for patients are important in glaucoma care. A patient who
resumes medication shortly before an ofﬁce visit after a gap in
therapy may appear to have an optimal pressure, yet visual ﬁeld
progression may have occurred. In this situation, it becomes
impossible to decide whether the pressure goal needs to be further
lowered or whether the pressure goal is appropriate but the patient
is progressing because of nonadherence to therapy, as the IOP is
above the goal for the period of nonadherence.
Medications work only for patients who take them.33 Glaucoma
patients may have variable clinical courses of the disease itself,
which this is further confounded by improper or irregular medi-
cation use. Greater awareness among physicians of the widespread
nature of nonadherence is a very important component of patient
care.34
There are certain ways by which patients' compliance can be
improved. The most important of them appears to be good
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disease, and an explanation of the role and importance of the
medications advised. It is equally important to simplify the pre-
scribed regimen by giving ﬁxed combinations wherever possible, to
limit the number of eye drops being used by the patient. If a patient
admits that the cause of poor compliance is the cost of the medi-
cine, then the treating physician should consider prescribing
equally efﬁcacious drugs with a lower cost or consider surgical or
laser treatment for the patient.References
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